[Correspondence] Early impact of RSV vaccination in older adults in England

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine evaluation. A 2023–24 vaccine effectiveness analysis of immunocompetent adults aged 60 years or older in the USA showed 80% (95% CI 71–85) protection against respiratory syncytial virus (RSV)-associated hospital admissions.1 In England, the UK Joint Committee on Vaccination and Immunisation advised an initial programme for those turning 75 years old, with a catch-up to age 79 years, pending further data on protection of those who are older.